Neon Therapeutics (NTGN) Downgraded by Zacks Investment Research to Hold
Zacks Investment Research cut shares of Neon Therapeutics (NASDAQ:NTGN) from a buy rating to a hold rating in a report released on Saturday morning.
According to Zacks, “Neon Therapeutics Inc. is a clinical-stage immuno-oncology company. It engaged in developing neoantigen-based therapeutics for the treatment of cancer by directing the immune system. The company’s product pipeline consists of NEO-PV-01, NEO-PTC-01 and NEO-SV-01 which are in clinical stage. Neon Therapeutics Inc. is based in Cambridge, United States. “
Separately, ValuEngine cut shares of Neon Therapeutics from a buy rating to a hold rating in a research report on Wednesday, January 2nd. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Neon Therapeutics has a consensus rating of Buy and a consensus price target of $17.83.
Neon Therapeutics (NASDAQ:NTGN) last released its quarterly earnings data on Monday, March 11th. The company reported ($0.84) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.73) by ($0.11). As a group, equities research analysts expect that Neon Therapeutics will post -2.66 earnings per share for the current year.
A number of large investors have recently bought and sold shares of the stock. FMR LLC lifted its position in Neon Therapeutics by 1.1% during the fourth quarter. FMR LLC now owns 2,079,669 shares of the company’s stock valued at $10,461,000 after acquiring an additional 23,075 shares during the last quarter. Partner Investment Management L.P. lifted its position in Neon Therapeutics by 32,903.8% during the third quarter. Partner Investment Management L.P. now owns 832,355 shares of the company’s stock valued at $5,841,000 after acquiring an additional 829,833 shares during the last quarter. Pharmstandard International S.A. purchased a new stake in Neon Therapeutics during the third quarter valued at approximately $5,027,000. Hillhouse Capital Advisors Ltd. purchased a new stake in Neon Therapeutics during the fourth quarter valued at approximately $1,572,000. Finally, BlackRock Inc. lifted its position in Neon Therapeutics by 12.0% during the fourth quarter. BlackRock Inc. now owns 307,782 shares of the company’s stock valued at $1,548,000 after acquiring an additional 32,943 shares during the last quarter. 72.08% of the stock is owned by institutional investors.
Neon Therapeutics Company Profile
Neon Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in developing neoantigen-targeted therapies for cancers in the United States. It is developing NEO-PV-01, a neoantigen vaccine that is in Phase Ib clinical trial in combination with nivolumab for the treatment of metastatic melanoma, non-small cell lung cancer, and bladder cancer; NEO-PTC-01, a neoantigen T cell therapy for the treatment of solid tumors; and NEO-SV-01, a neoantigen vaccine for the treatment of estrogen-receptor-positive breast cancer.
See Also: Ex-Dividend
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Neon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.